Liquidia Technologies Inc (LQDA)

Currency in USD
74.510
+2.410(+3.34%)
Real-time Data·
LQDA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
71.53076.000
52 wk Range
21.14593.610
Key Statistics
Prev. Close
72.1
Open
71.98
Day's Range
71.53-76
52 wk Range
21.145-93.61
Volume
517.16K
Average Volume (3m)
1.92M
1-Year Change
185.5117%
Book Value / Share
2.19
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
LQDA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
107.750
Upside
+44.61%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year

Liquidia Technologies Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Analyst Ratings

6 Buy
2 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 107.750
(+44.61% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Wells Fargo
Buy108.00+45.08%62.00Maintain13/08/2026
LifeSci Capital
Hold90.00+20.90%-Downgrade12/08/2026
H.C. Wainwright
Buy130.00+74.64%75.00Maintain24/07/2026
BofA Securities
Hold79.00+6.13%64.00Downgrade29/06/2026
H.C. Wainwright
Buy75.00+0.75%67.00Maintain05/06/2026

Liquidia Technologies Inc Earnings Call Summary for Q2/2026

  • Liquidia posted Q2 2026 EPS of $0.74, missing estimates of $0.76, while revenue beat at $171.68M vs. $170.98M forecast; shares fell 4.6% to $84.
  • YUTREPIA sales surged 31% sequentially to $170.4M, capturing nearly 30% of inhaled prostacyclin market share on net revenue basis.
  • Company reported net income of $74.7M and adjusted EBITDA of $96.3M, marking fourth consecutive quarter of rising profitability.
  • Management reaffirmed guidance for over $1B in net revenue in 2027, despite planned doubling of R&D spending in H2 2026 for L606 Phase III trial.
  • Cash position strengthened to $284.2M, up $61.4M from Q1, with over 5,000 patients on therapy and 1,100+ prescribing physicians.
Last Updated: 12/08/2026, 11:38 pm
Read Full Transcript

Earnings

Latest Release
12/08/2026
EPS / Forecast
0.74 / 0.76
Revenue / Forecast
171.68M / 170.98M
EPS Revisions
Last 90 days

LQDA Income Statement

Compare LQDA to Peers and Sector

Metrics to compare
LQDA
Peers
Sector
Relationship
P/E Ratio
46.6x−6.8x−0.4x
PEG Ratio
0.26−1.220.00
Price/Book
33.1x0.9x2.6x
Price / LTM Sales
14.3x4.8x3.1x
Upside (Analyst Target)
51.2%60.3%48.4%
Fair Value Upside
Unlock4.3%6.5%Unlock

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company’s lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil which is in phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). In addition, the company offers PRINT technology which allows to engineer and manufacture uniform drug particles with precise control over the size, three-dimensional geometric shape, and chemical composition of the particles. It has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD; Vectura; The University of North Carolina at Chapel Hill; GlaxoSmithKline; Alcon Inc; and promotion Agreement with Sandoz. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.

Employees
216

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
22.64M25.46%1.78B
Other Institutional Investors
49.69M55.88%3.92B
Public Companies & Retail Investors
16.60M18.66%1.31B
Total
88.93M100.00%7.01B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.11.87%10,551,901831,384
Farallon Capital Management, L.L.C.9.41%8,365,038659,081

People Also Watch

52.87
VECO
-1.33%
201.16
RVMD
-0.42%
18.59
ALMU
+5.63%

FAQ

What Is the Liquidia Technologies (LQDA) Stock Price Today?

The Liquidia Technologies stock price today is 74.510 USD.

What Stock Exchange Does Liquidia Technologies Trade On?

Liquidia Technologies is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Liquidia Technologies?

The stock symbol for Liquidia Technologies is "LQDA."

What Is the Liquidia Technologies Market Cap?

As of today, Liquidia Technologies market cap is 6.700B USD.

What Is Liquidia Technologies's Earnings Per Share (TTM)?

The Liquidia Technologies EPS (TTM) is 1.478.

When Is the Next Liquidia Technologies Earnings Date?

Liquidia Technologies will release its next earnings report on 10/11/2026.

From a Technical Analysis Perspective, Is LQDA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Liquidia Technologies Stock Split?

Liquidia Technologies has split 0 times.

How Many Employees Does Liquidia Technologies Have?

Liquidia Technologies has 216 employees.

What is the current trading status of Liquidia Technologies (LQDA)?

As of 14/08/2026, Liquidia Technologies (LQDA) is trading at a price of 74.510 USD, with a previous close of 72.100 USD. The stock has fluctuated within a day range of 71.530 USD to 76.000 USD, while its 52-week range spans from 21.145 USD to 93.610 USD.

What Is Liquidia Technologies (LQDA) Price Target According to Analysts?

The average 12-month price target for Liquidia Technologies is 107.750 USD, with a high estimate of 130 USD and a low estimate of 90 USD. 6 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +44.61% Upside potential.

What Is the LQDA Premarket Price?

LQDA's last pre-market stock price is 71.520 USD. The pre-market share volume is 26,140.000, and the stock has decreased by -0.580, or -0.800%.

What Is the LQDA After Hours Price?

LQDA's last after hours stock price is 73.000 USD, the stock has decreased by 0.900, or 1.250%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.